Association of adiponectin gene expression and oxidative stress markers with β-thalassemia major patients in Babylon City
Abstract
Beta-thalassemia major (β-TM) is a severe hereditary hematological illness marked by a substantial decrease or total lack of beta-globin chain production, resulting in inefficient erythropoiesis and persistent hemolytic anemia. The objective of this r e search was to examine the associ ation of gene expression of adiponectin with β-TM disease compared with the internal control gene GAPDH using the qPCR technique. The study also verified the association of oxidative stress with β-TM disease by est i mating the levels of MDA and SOD using the ELISA assay. Furthermore, we assessed the levels of clinical biomarkers in the beta-thalassemia major patients (G2) as compared with the control (G1). The case-control study was conducted on 150 partic i pants, 75 of whom were beta-thalassemia major patients (G2) and 75 of whom were healthy contr ols (G1). The participants' age ranged 7 to 14 years, and all of them were non-smokers and did not suffer from other diseases in order to exclude the resulting harms, thus enhanc ing the reliability of the results. The c linical examinations were conducted to estimate biomarkers (creatinine, b lood urea, t otal bilirubin, t otal protein, HCT, HGB, PLT, RBCs, and WBCs) at Babylon Hospital for Women and Children , and the gene expression test s for the adiponectin gene and the ELISA assay to estimate MDA and SOD were conducted at the labo r atories of the College of Science, Al-Qadisiyah University. Significant differences were observed between the groups in the adiponectin gene expression, MDA, and SOD levels, and also the biomedical parameters (creatinine, blood urea, total bilirubin, total protein, HCT, HGB, PLT, RBCs, and WBCs). Th us, the gene expression analysis of adiponectin using the GAPDH gene as a reference gene in the qPCR technique showed a dec line in the level of gene expression of adiponectin in the β-TM patients (G2) com pared with the control (G1) . The results of the fold change (2-ΔΔct) were 0.024 , and the efficiency of sample amplif i cation ranged 91 % to 95%, indicating the quality of the gene expression results. The ELISA measurements of MDA and SOD revealed an incre ase in their levels, where the ir mean value s were high in the β-TM patients (G2) compared with the control (G1), highlighting a significant difference between the two groups. The study found an increase in the level s of b lood u rea, t otal bili rubin, PLT, and WBCs, as the mean values for them were high in G2 compared with G1. At the same time, a decrease was found in the level s of creatinine, t otal pr otein, HCT, HGB, and RBCs, as their mean values were low in G2 , com pared with G1. Also, we observed a reduced adiponectin gene expression. In the study, an increase in MDA levels led to higher SOD levels, suggest ing a compensatory response to oxidant stress damage. These indicators can be used to diagnose or monitor β-TM di s ease.References
Abd, D. A.-A., Lafta, F. M., & Alwan, Y. F. (2022). The association between plasma IL-6 levels and several thalassemia-related clinical features in Iraqi patients. International Journal of Health Sciences, 6(S6), 548–561.
Abdulhaleem, F. A., Al-Qaisi, A. H. J., Jamil, D. M., Redwan, A. M., & Zulkifli, N. W. (2025). Evaluation of serum leptin and ferritin levels in females with beta thalassemia major. Al-Nahrain Journal of Science, 28(1), 1–7.
Ahmadi, A., Hosseini, S., Dorgalaleh, A., Hassani, S., Tabibian, S., Tavasoli, B., Shabannezhad, A., Taheri, M., & Shams, M. (2024). Natural anticoagulant protein levels in patients with beta-thalassemia major: A case-control study. Journal of hematology, 13(1–2), 23–28.
Akbarnejad, A. A., Mahjoub, S., Tamaddoni, A., Masrour-Roudsari, J., Seyedmajidi, S. A., & Ghasempour, M. (2022). Salivary oxidative stress, total protein, iron and pH in children with β-thalassemia major and their correlation with dental caries. Journal of Dentistry, 23(3), 266–271.
Akbayram, H. T., & Örkmez, M. (2020). Relationship between platelet counts, mean platelet volume, platecrit and beta thalassemia carriers. Journal of Contemporary Medicine, 10(3), 302–306.
Al-Dagestani, E. A. H., Hamza, M. A., & Yusif, N. Y. (2025). A comparative study of liver and kidney function indicators in patients with beta-thalassemia major and beta-thalassemia trait. Al-Anbar Medical Journal, 21(3), 191–197.
Al-Dhalimi, A. A. A. B., & Al-Abady, Z. N. (2025). Analysis of the relationship between NLRP3, ferritin, MDA, and catalase enzyme in patients with beta-thalassemia major: A clinical study. Journal of Biomedicine and Biochemistry, 4(2), 1–20.
Ali, S., Mumtaz, S., Shakir, H. A., Khan, M., Tahir, H. M., Mumtaz, S., Mughal, T. A., Hassan, A., Kazmi, S. A. R., Sadia, Irfan, M., & Khan, M. A. (2021). Current status of beta-thalassemia and its treatment strategies. Molecular Genetics and Genomic Medicine, 9(12), e1788.
Arian, M., Oghazian, M. B., Nour El Dine, M. H., Valinejadi, A., Badiee, Z., Soleimani, M., & Sahebkar, A. (2025). Biochemical markers of early renal dysfunction in patients with β-thalassemia major: A systematic review and meta-analysis. Current Medicinal Chemistry, 32(13), 2572–2597.
Arsalan, H. M., Abbas, N., Aslam, S., Yasmeen, N., Rehman, R., Farooq, N. (2020). Evaluation of circulating biochemical and anti-oxidative biomarkers in patients with beta-thalassemia from Lahore Pakistan. Journal of Sheikh Zayed Medical College, 11(2), 34–38.
Baird, D. C., Batten, S. H., & Sparks, S. K. (2022). Alpha- and beta-thalassemia: Rapid evidence review. American Family Physician, 105(3), 272–280.
Caprari, P., Profumo, E., Massimi, S., Buttari, B., Riganò, R., Regine, V., Gabbianelli, M., Rossi, S., Risoluti, R., Materazzi, S., Gullifa, G., Maffei, L., & Sorrentino, F. (2023). Hemorheological profiles and chronic inflammation markers in transfusion-dependent and non-transfusion- dependent thalassemia. Frontiers in Molecular Biosciences, 9, 1108896.
Chiew, J. Y., Thiruchelvam, J., Bin Rahmat, M. A., William, S. P., Bin Shafien, Z. I., & Banerjee, K. G. (2021). The key complications of beta thalassemia major: A review and update. International Journal of Research in Medical Sciences, 9(6), 1846–1852.
Coates T. D. (2024). Higher hemoglobin is better in thalassemia. Blood, 143(10), 842–844.
Daar, S., Al-Naamani, K., De Sanctis, V., Al Rahbi, S., Al Zadjali, S., Khan, H., Panjwani, V., & Al-Khabori, M. (2023). Mortality and complications in Omani patients with beta-thalassemia major: A long-term follow-up study. Acta Bio-Medica: Atenei Parmensis, 94(4), e2023191.
Gagliardi, I., Celico, M., Gamberini, M. R., Pontrelli, M., Fortini, M., Carnevale, A., Napoli, N., Zatelli, M. C., & Ambrosio, M. R. (2022). Efficacy and safety of teriparatide in beta-thalassemia major associated osteoporosis: A real-life experience. Calcified Tissue International, 111(1), 56–65.
Harbi, N. S., Jawad, A. H., & Alsalman, F. K. (2020). Evaluation of adipokines concentration in Iraqi patients with major and minor beta thalassemia. Reports of Biochemistry and Molecular Biology, 9(2), 209–215.
Hasoon, I. G., Shani, W. S., & Radi, A. M. (2020). The association of hepcidin with some inflammatory markers in β-thalassemia major patients of Basrah Province. EurAsian Journal of BioSciences, 14, 7285–7289.
Hussain, G. M., Abdullah, M. A., & Hussein, N. Y. (2023). Association of the changes in hepatic enzymes, bilirubin, and plasma proteins with beta-thalassemia in iron over loaded-patients. Journal of Advanced Biotechnology and Experimental Therapeutics, 6(2), 429-435.
Inteek, H. H., & Madhkhoor, S. R. (2024). Investigating oxidative stress and antioxidant dynamics in beta-thalassemia major: A comparative study from Al-Diwaniyah, Iraq. Journal of Applied Hematology, 15(4), 263–269.
Islam, M. T., Sultana, N., Sarker, S. K., Hossain, T., Tasnim, S., Al Mahmud-Un-Nabi, M., Safain, K. S., Biswas, A., Hossain, S. R., Begum, M. N., Islam, M. S., Noor, F. A., Bhuyan, G. S., Shirin, T., Muraduzzaman, A. K. M., Khan, W. A., Hossain, A. K. M. E., Shekhar, H. U., Nabi, A. H. M. N., Qadri, S. S., Qadri, F., & Mannoor, K. (2021). Association of diverse population of red blood cells with different disease manifestations in patients with beta-thalassemia. Meta Gene, 27, 100846.
Jaafari, Z., Sadidi, N., Abdolahinia, Z., & Shahesmaeili, A. (2022). Prevalence of depression among Iranian patients with beta-thalassemia major: A systematic review and meta-analysis. Iranian Journal of Medical Sciences, 47(1), 15–24.
Khawaji, M. M., Hazzazi, A. A., Ageeli, M. H., Mawkili, Y. H., Darbashi, A. H., Abo Kathiyah, A. M. A., & Humedi, R. A. (2020). Clinical and hematological features among β-thalassemia major patients in Jazan Region: A hospital-based study. Journal of Family Medicine and Primary Care, 9(1), 412–417.
Lal, A., Wong, T., Keel, S., Pagano, M., Chung, J., Kamdar, A., Rao, L., Ikeda, A., Puthenveetil, G., Shah, S., Yu, J., & Vichinsky, E. (2021). The transfusion management of beta thalassemia in the United States. Transfusion, 61(10), 3027–3039.
Mahesar, A., Mazari, M. A., Faizan, S. M., Farzana, T., Bukhari, J. N. A., & Shamsi, T. S. (2020). Platelet refractoriness during BONE marrow transplantation, comparison in aplasticanemia and beta thalassemia major patients. An experience of public sector BMT unit in Pakistan. Biology of Blood and Marrow Transplantation, 26(3), S210–S211.
Musallam, K. M., Lombard, L., Kistler, K. D., Arregui, M., Gilroy, K. S., Chamberlain, C., Zagadailov, E., Ruiz, K., & Taher, A. T. (2023). Epidemiology of clinically significant forms of alpha- and beta-thalassemia: A global map of evidence and gaps. American Journal of Hematology, 98(9), 1436–1451.
Mustafa, S. M., Alizadeh, S., Saleh, A. H., Majidi, Z., Mousavi, S. H., & Khatib, Z. K. (2022). Evaluation the concentration of hormonal and cytokine parameters in beta thalassemia major patients. Internal Medicine Today, 29(1), 2–8.
Nahi, S. M., & Jabir, F. A. (2023). Correlation of hepcidin with hemoglobin and iron parameters in Iraqi patients with beta-thalassemia major. Al-Qadisiyah Medical Journal, 19(1), 9–14.
Rashid, M. A. U. H., & Abbasi, S.-U.-R. S. (2020). Theorizing beta thalassemia major: An overview of health sociology. International and Multidisciplinary Journal of Social Sciences, 9(1), 51–75.
Romadhon, P. Z., Ashariati, A., Bintoro, S. U. Y., Suryantoro, S. D., Windradi, C., Mahdi, B. A., Widyastuti, K. N., Widiasi, E. D., Prahasanti, K., Putri, A. E., & Yusoff, N. M. (2024). Existing tubular injury in β-thalassemia major patients receiving iron chelating agents with normal creatinine level in East Java, Indonesia. Hemoglobin, 48(5), 301–307.
Sadeghi, M. V., Mirghorbani, M., & Akbari, R. (2021). β-Thalassemia minor and renal tubular dysfunction: Is there any association? BMC Nephrology, 22(1), 404.
Sadiq, J. M., & Hasan, B. Q. (2024). Immunological evaluation of interleukin-6 and 8 in β-thalassemia patients in Iraq. Egyptian Academic Journal of Biological Sciences C Physiology and Molecular Biology, 16(1), 113–121.
Sarhat, E. R., Hamad, M. S., & Khalaf, S. J. (2020). Leptin, adiponectin, and interleukin-6 levels among beta thalassaemia patients. Science Advances, 14(127), 99–105.
Shakir, A. A., & Al-Husseini, A. M. H. (2021). Measurement the levels of catalase activity, malondialdehyde and ferritin in beta-thalassemia major patient. Medico Legal Update, 21(2), 22–26.
Tzounakas, V. L., Anastasiadi, A. T., Stefanoni, D., Cendali, F., Bertolone, L., Gamboni, F., Dzieciatkowska, M., Rousakis, P., Vergaki, A., Soulakis, V., Tsitsilonis, O. E., Stamoulis, K., Papassideri, I. S., Kriebardis, A. G., D'Alessandro, A., & Antonelou, M. H. (2022). Beta thalassemia minor is a beneficial determinant of red blood cell storage lesion. Haematologica, 107(1), 112–125.
Xu, X., & Wu, X. (2019). Epidemiology and treatment of beta thalassemia major in China. Pediatric Investigation, 4(1), 43–47.
Yadav, P. K., & Singh, A. K. (2022). A review of iron overload in beta-thalassemia major, and a discussion on alternative potent iron chelation targets. Plasmatology, 16, 1–9.
Copyright (c) 2025 Regulatory Mechanisms in Biosystems
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons «Attribution» 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
